Am ndm nts to th Claims:

This listing of claims will replace all prior versions, and listing of claims in the application:

Listing of Claims:

Claims 1-107 (canceled).

Claim 108 (new). A method of providing hormone replacement therapy in a post-menopausal woman in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I or II, having the structures

$$R_1$$
 R_2
 R_5
 R_6
 $(CH_2)_{n-Y}$
 R_7
 R_8
 R_8
 R_8
 R_8
 R_8
 R_8
 R_9
 R

wherein:

 R_1 is selected from H, OH or the C_1 - C_{12} esters (straight chain or branched) or C_1 - C_{12} (straight chain or branched or cyclic) alkyl ethers thereof, or halogens; or C_1 - C_4 halogenated ethers including triflouromethyl ether and trichloromethyl ether.

 R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from H, OH or the C_1 - C_{12} esters (straight chain or branched) or C_1 - C_{12} alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C_1 - C_4 halogenated ethers including triflouromethyl ether and trichloromethyl ether, cyano, C_1 - C_6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R_1 is H, R_2 is not OH.

X is selected from H, C₁-C₆ alkyl, cyano, nitro, trifluoromethyl, halogen; n is 2 or 3;

Y is selected from:

a) the moiety:



wherein R_7 and R_8 are independently selected from the group of H, C_1 - C_6 alkyl, or phenyl optionally substituted by CN, C_1 - C_6 alkyl (straight chain or branched), C_1 - C_6 alkoxy (straight chain or branched), halogen, -OH, -CF₃, or -OCF₃;

- b) a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C₁C₄ alkyl)-, -N=, and -S(O)_m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C₁-C₄ alkyl, trihalomethyl, C₁-C₄ alkoxy, trihalomethoxy, C₁-C₄ acyloxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, hydroxy (C₁-C₄)alkyl, -CO₂H-, -CN-, -CONHR₁-, -NH₂-, C₁-C₄ alkylamino, di(C₁-C₄)alkylamino, -NHSO₂R₁-, -NHCOR₁-, -NO₂, and phenyl optionally substituted with 1-3 (C₁-C₄)alkyl;
- c) a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C₁C₄ alkyl)-, -N=, and -S(O)_m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C₁-C₄ alkyl, trihalomethyl, C₁-C₄ alkoxy, trihalomethoxy, C₁-C₄ acyloxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, hydroxy (C₁-C₄)alkyl, -CO₂H-, -CN-, -CONHR₁-, -NH₂-, C₁-C₄ alkylamino, di(C₁-C₄)alkylamino, -NHSO₂R₁-, -NHCOR₁-, -NO₂, and phenyl optionally substituted with 1-3 (C₁-C₄)alkyl;
- d) a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C₁C₄ alkyl)-, -N=, and -S(O)_m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C₁-C₄ alkyl, trihalomethyl, C₁-C₄ alkoxy, trihalomethoxy, C₁-C₄ acyloxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, hydroxy (C₁-C₄)alkyl, -CO₂H-, -CN-, -CONHR₁-, -NH₂-, C₁-C₄ alkylamino, di(C₁-C₄)alkylamino, -NHSO₂R₁-, -NHCOR₁-, -NO₂, and phenyl optionally substituted with 1-3 (C₁-C₄)alkyl;; or

e) a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C_1C_4 alkyl)-, and -S(O)_m-, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C_1 - C_4 alkyl, trihalomethyl, C_1 - C_4 alkoxy, trihalomethoxy, C_1 - C_4 acyloxy, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, hydroxy (C_1 - C_4)alkyl, - CO_2 H-, -CN-, - $CONHR_1$ -, - NH_2 -, C_1 - C_4 alkylamino, di(C_1 - C_4)alkylamino, - $NHSO_2R_1$ -, - $NHCOR_1$ -, - NO_2 , and phenyl optionally substituted with 1-3 (C_1 - C_4) alkyl; or a pharmaceutically acceptable salt thereof.

Claim 109 (new). The method according to Claim 108 wherein:

R₁ is selected from H, OH or the C₁-C₄ esters or alkyl ethers thereof, halogen;

 R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from H, OH or the C_1 - C_4 esters or alkyl ethers thereof, halogen, cyano, C_1 - C_6 alkyl, or trifluoromethyl, with the proviso that, when R_1 is H, R_2 is not OH;

X is selected from H, C_1 - C_6 alkyl, cyano, nitro, triflouromethyl, halogen; Y is the moiety

 R_7 and R_8 are selected independently from H, C_1 - C_6 alkyl, or combined by -(CH_2)p-, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C_1 - C_4 alkyl, trihalomethyl, C_1 - C_4 alkoxy, trihalomethoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, hydroxy (C_1 - C_4)alkyl, - CO_2 H, -CN, - $CONH(C_1$ - C_4), - NH_2 , C_1 - C_4 alkylamino, di(C_1 - C_4)alkylamino, - $NHSO_2(C_1$ - C_4), - $NHCO(C_1$ - C_4), and - NO_2 ; or a pharmaceutically acceptable salt thereof.

Claim 110 (new). The method according to Claim 108 wherein:

R₁ is OH;

 R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from H, OH or the C_1 - C_4 esters or alkyl ethers thereof, halogen, cyano, C_1 - C_6 alkyl, or trifluoromethyl, with the proviso that, when R_1 is H, R_2 is not OH;

X is selected from the group of CI, NO₂, CN, CF₃, or CH₃;

Y is the moiety

 R_7 and R_8 are concatenated together as -(CH₂)_r-, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C_1 - C_4 alkyl, trihalomethyl, C_1 - C_4 alkoxy, trihalomethoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, hydroxy (C_1 - C_4)alkyl, - CO_2 H, -CN, - $CONH(C_1$ - C_4), - NH_2 , C_1 - C_4 alkylamino, di(C_1 - C_4)alkylamino, - $NHSO_2(C_1$ - C_4), - $NHCO(C_1$ - C_4), and - NO_2 ;

or a pharmaceutically acceptable salt thereof.

Claim 111 (new). The method according to Claim 108, wherein the compound is 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

Claim 112 (new). The method according to Claim 108, wherein the compound is 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.